FERRAU', Francesco
 Distribuzione geografica
Continente #
NA - Nord America 3.669
AS - Asia 2.505
EU - Europa 2.344
SA - Sud America 895
AF - Africa 63
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 2
AN - Antartide 1
Totale 9.481
Nazione #
US - Stati Uniti d'America 3.586
SG - Singapore 1.079
BR - Brasile 797
CN - Cina 744
IE - Irlanda 587
SE - Svezia 498
IT - Italia 341
HK - Hong Kong 300
DE - Germania 194
PL - Polonia 169
GB - Regno Unito 145
VN - Vietnam 145
RU - Federazione Russa 94
FI - Finlandia 80
FR - Francia 78
IN - India 56
CA - Canada 37
UA - Ucraina 37
AR - Argentina 34
MX - Messico 34
BE - Belgio 27
ZA - Sudafrica 26
TR - Turchia 25
ID - Indonesia 20
AT - Austria 18
BD - Bangladesh 18
EC - Ecuador 17
IQ - Iraq 16
UZ - Uzbekistan 16
CO - Colombia 14
JP - Giappone 14
CZ - Repubblica Ceca 13
NL - Olanda 13
PK - Pakistan 11
ES - Italia 10
LT - Lituania 10
MA - Marocco 9
VE - Venezuela 9
JO - Giordania 7
KE - Kenya 7
KG - Kirghizistan 7
PE - Perù 6
PY - Paraguay 6
CI - Costa d'Avorio 5
CL - Cile 5
IL - Israele 5
NP - Nepal 5
TN - Tunisia 5
AE - Emirati Arabi Uniti 4
DZ - Algeria 4
PA - Panama 4
SA - Arabia Saudita 4
UY - Uruguay 4
AL - Albania 3
AZ - Azerbaigian 3
BY - Bielorussia 3
CH - Svizzera 3
EE - Estonia 3
GE - Georgia 3
LV - Lettonia 3
NG - Nigeria 3
OM - Oman 3
AM - Armenia 2
BO - Bolivia 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
GR - Grecia 2
HR - Croazia 2
LB - Libano 2
LK - Sri Lanka 2
MD - Moldavia 2
MY - Malesia 2
NO - Norvegia 2
PH - Filippine 2
PT - Portogallo 2
SN - Senegal 2
TH - Thailandia 2
XK - ???statistics.table.value.countryCode.XK??? 2
AO - Angola 1
AQ - Antartide 1
AU - Australia 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BN - Brunei Darussalam 1
CG - Congo 1
DK - Danimarca 1
GT - Guatemala 1
IR - Iran 1
JM - Giamaica 1
KR - Corea 1
KW - Kuwait 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LC - Santa Lucia 1
LU - Lussemburgo 1
MK - Macedonia 1
MN - Mongolia 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 9.480
Città #
Dublin 586
Ashburn 525
Singapore 510
Chandler 492
Dallas 467
Beijing 326
Nyköping 303
Hong Kong 299
Warsaw 159
Messina 151
Jacksonville 124
Los Angeles 117
The Dalles 110
Munich 109
Princeton 102
Medford 94
New York 78
Dearborn 77
Ann Arbor 76
Des Moines 71
Cambridge 65
São Paulo 57
Lancaster 54
Ho Chi Minh City 43
Shenyang 40
Redondo Beach 38
Buffalo 37
Jinan 34
Moscow 33
Tianjin 31
Boardman 29
Brooklyn 29
Hyderabad 27
Rio de Janeiro 27
Brussels 26
Hanoi 26
Wilmington 26
Belo Horizonte 24
Helsinki 24
Seattle 24
Turku 24
Frankfurt am Main 22
Houston 22
Nanjing 22
London 21
Catania 20
Curitiba 19
Guangzhou 18
Johannesburg 17
San Mateo 17
Tashkent 16
Jakarta 15
Montreal 15
Santa Clara 15
Vienna 15
Zhengzhou 15
Council Bluffs 14
Dong Ket 14
Pune 14
Tokyo 14
Atlanta 13
Denver 13
Stockholm 13
Brasília 12
Bremen 12
Campinas 12
Düsseldorf 12
Hangzhou 12
Nanchang 12
Poplar 12
Ankara 11
Ningbo 11
Porto Alegre 11
Haikou 10
Lauterbourg 10
Taizhou 10
Woodbridge 10
Boston 9
Mexico City 9
Milan 9
Nuremberg 9
Orem 9
San Francisco 9
Toronto 9
Chennai 8
Goiânia 8
Hebei 8
Rome 8
Baghdad 7
Bexley 7
Bishkek 7
Brno 7
Changsha 7
Fairfield 7
Fortaleza 7
Franca 7
Fuzhou 7
Norwalk 7
Quito 7
Ribeirão Preto 7
Totale 6.194
Nome #
Aggressive pituitary adenomas: the dark side of the moon 184
Acromegaly is more severe in patients with AHR or AIP gene variants living in highly polluted areas 174
Aggiornamento sulla chirurgia ipofisaria per via endoscopica: indicazioni, vantaggi e limiti 166
Clinical management of critically ill patients with Cushing's disease due to ACTH-secreting pituitary macroadenomas: effectiveness of presurgical treatment with pasireotide 153
Diabetes secondary to acromegaly: Physiopathology, clinical features and effects of treatment 147
Cardiovascular events in acromegaly: distinct role of Agatston and Framingham score in the 5-year prediction. 146
Cyberknife stereotactic treatment of pituitary adenomas: A single center experience using different irradiation schemes and modalities 141
Global Cushing's disease epidemiology: a systematic review and meta-analysis of observational studies 130
Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience 128
Global epidemiology of acromegaly: A systematic review and meta-analysis 128
PRIMARY EMPTY SELLA IS ASSOCIATED WITH INCREASED CARDIOVASCULAR RISK, REGARDLESS THE OCCURRENCE OF PITUITARY DYSFUNCTION 127
Acromegaly, genetic variants of the aryl hydrocarbon receptor pathway and environmental burden 127
Increased prevalence of acromegaly in a highly polluted area. 125
Peptide receptor radionuclide therapy with 111IN-DTPA-Octreotide in a woman with Cabergoline-resistant giant prolactinoma 125
GSTP1 gene methylation and AHR rs2066853 variant predict resistance to first generation somatostatin analogs in patients with acromegaly 124
Increased serum interleukin-22 levels in patients with PRL-secreting and non-functioning pituitary macroadenomas. 122
P-57 Increased prevalence of acromegaly in an industrialized area of north-east of Sicily: a case-control study 121
Course of Pregnancy in Cushing Disease under Different Management Approaches (No Treatment, Surgery, Gamma-Knife or Ketoconazole) 121
Effectiveness and safety of long-term pegvisomant administration in patients with acromegaly not controlled by other therapies: experience of an Italian center. 120
High bone marrow fat in patients with Cushing’s syndrome and vertebral fractures 116
Pasireotide treatment reduces cardiometabolic risk in Cushing's disease patients: an Italian, multicenter study 111
Comment to ‘glucocorticoid resistance syndrome caused by a novel nr3c1 point mutation’ by al argan et al. 109
Resistance to somatostatin analogues is associated with GSTP1 gene methylation and AHR rs2066853 variant in acromegaly patients 108
An extremely rare association of TSH-secreting pituitary adenoma, metastatic neuroendocrine tumor and Cushing’s syndrome in a patient with MEN-1 gene mutation 108
Increased prevalence of restless legs syndrome in patients with acromegaly and effects on quality of life assessed by Acro-QoL. 107
Multidisciplinary management of pituitary apoplexy 107
Analysis of GPR101 and AIP genes mutations in acromegaly: a multicentric study 105
Epidemiologia degli adenomi ipofisari nel nord-est della Sicilia 104
Course of pregnancies in women with Cushing's disease treated by gamma-knife 102
Increased frequency of the rs2066853 variant of aryl hydrocarbon receptor gene in patients with acromegaly 102
Effects of cyberknife radiotherapy treatment of pituitary adenomas 101
Effects of pasireotide treatment on cardio-metabolic risk in patients with Cushing's disease: an Italian, multicenter study 100
Thyroid nodules in growth hormone replaced patients. 100
Cardiometabolic Risk in Acromegaly: A Review With a Focus on Pasireotide 100
Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective 99
Biochemical control and clinical improvement is induced by long-term pasireotide administration in the majority of patients with Cushing[apos]s disease persistent after pituitary surgery 98
Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease--report of a case and literature review. 96
Establishment of a protocol to extend the lifespan of human hormone-secreting pituitary adenoma cells 95
From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell? 95
First report on persistent remission of acromegaly after withdrawal of long-term pegvisomant monotherapy 94
Adrenal Cushing Syndrome: Diagnosis and Management in a 10-Year-Old Boy with Carney Complex 93
Temozolomide-induced shrinkage of a pituitary carcinoma. 91
Health-related quality of life in patients with Cushing's syndrome 90
Increased interleukin 22 circulating levels in patients with tumors involving the hypothalamic-pituitary region 90
An unusual case of idiopathic hyperprolactinemia 89
Pitfalls in the 2017 TNM Classification of Thyroid Carcinoma 89
Adrenocorticotropin responsiveness to acute octreotide administration is not affected by mifepristone premedication in patients with Cushing's disease. 88
Adrenal cancer in neurofibromatosis type 1: case report and DNA analysis 88
Absence of GNAS1 mutations in somatotropinomas from AIPmut positive patients: possible implications for phenotype. 88
Methylome Analysis in Nonfunctioning and GH-Secreting Pituitary Adenomas 87
Increased serum brain natriuretic peptide levels are a major predictor of myocardial hypertrophy in acromegalic patients. 86
A New Clinical Model to Estimate the Pre-Test Probability of Cushing’s Syndrome: The Cushing Score 86
MicroRNAs expression in pituitary tumors: differences related to functional status, pathological features, and clinical behavior 84
Visceral adiposity index as an indicator of cardiometabolic risk in patients treated for craniopharyngioma 82
First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment. 81
Peptide receptor radionuclide therapy (PRRT) in patients with giant aggressive pituitary tumors: experience of an Italian referral center and review of literature 80
Paradoxical GH increase during OGTT is associated to first-generation somatostatin analogs responsiveness in acromegaly 79
Endocrinologia & Malattie del Metabolismo 79
X-linked acrogigantism: a new condition of growth hormone excess. 76
Cabergoline-related impulse control disorder in an adolescent with a giant prolactinoma 74
The man with acromegaly who inspired the Shrek animated project. 74
Oral mucositis induced by treatment with soft gel formulation of levothyroxine 73
Genetic and epigenetic modulation of AHR pathway in GH-secreting pituitary tumors and effects on acromegaly clinical phenotype 72
Pregnancy after azathioprine therapy for ulcerative colitis in a woman with autoimmune premature ovarian failure and Addison's disease: HLA haplotype characterization. 72
Effects Of Epigenetic Changes In Gstp1 And Mgmt Gene On Clinicopathological Fatures Of Acromegaly Patients 72
Environmental Endocrinology and Endocrine Disruptors: Environmental Impact on the Hypothalamus–Pituitary Axis 71
Immunohistochemical localization and functional characterization of somatostatin receptor subtypes in a corticotropin releasing hormone-secreting adrenal phaeochromocytoma: review of the literature and report of a case 71
GPR101 variants in acromegaly: results from a large series of patients. 71
The ubiquitin-specific peptidase 8 (USP8) gene is frequently mutated in adenomas causing Cushing's disease 71
Epidemiology, course, and outcomes of Sars-CoV-2 infection in patients with acromegaly and Cushing’s disease: a monocentric experience in Southern Italy 70
Sequence analysis of the catalytic subunit of PKA in somatotroph adenomas 70
Somatic Deletion in Exon 10 of Aryl Hydrocarbon Receptor Gene in Human GH-Secreting Pituitary Tumors 70
Neoadjuvant Therapy for Neuroendocrine Neoplasms: Recent Progresses and Future Approaches 70
Landscape of familial isolated and young-onset pituitary adenomas: Prospective diagnosis in AIP mutation carriers 69
Trabecular bone score, bone marrow fat and vertebral fractures in cushing syndrome 68
Shrinkage of a pituitary metastasis of melanoma induced by pembrolizumab: a case report 68
An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis 67
Neuroendocrine neoplasms in the context of inherited tumor syndromes: a reappraisal focused on targeted therapies 67
Persistent severe visual field impairment is associated with obesity and tumour invasiveness, but not with pituitary dysfunction, in patients with craniopharyngioma 66
Role of pituitary dysfunction on cardiovascular risk in primary empty sella patients 66
How to diagnose and manage Cushing's disease during pregnancy, when hypercortisolism is mild? 64
Somatic USP8 mutations are frequent events in corticotroph tumor progression causing Nelson's tumor 64
Unique clinical picture in patients with X-linked acrogigantism 64
What factors have impact on glucocorticoid replacement in adrenal insufficiency: a real-life study 63
Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms 62
Metabolic comorbidities in Cushing's syndrome 61
The gene of the ubiquitin-specific protease 8 is frequently mutated in adenomas causing cushing's disease 60
Long-term cardiometabolic outcome in patients with pituitary adenoma diagnosed in chilhood and adolescence 59
New findings on presentation and outcome of patients with adrenocortical cancer: results from a national cohort study 58
Systemic comorbidities induce early vascular alterations in patients with active acromegaly. 58
The Enhanced Proteasomal Degradation of AIP Mutant Proteins Is a Mechanism for AIP Deficiency in AIP mutation-Associated Pituitary Adenomas 58
Tertiary hypercortisolism due to occult Cushing's syndrome 58
Metabolic syndrome in cushing's syndrome patients 58
What we have to know about corticosteroids use during Sars-Cov-2 infection 58
Gastroenteropancreatic neuroendocrine neoplasms and inflammation: A complex cross-talk with relevant clinical implications 57
Clinical Consequences of Variable Results in the Measurement of Free Thyroid Hormones: Unusual Presentation of a Family with a Novel Variant in the THRB Gene Causing Resistance to Thyroid Hormone Syndrome 56
Somatic mutations in USP8 are frequent events in pituitary tumors causing Nelson's syndrome 55
Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study 55
A pharmacoeconomic analysis from Italian guidelines for the management of prolactinomas 54
L'acromegalia 54
Totale 9.040
Categoria #
all - tutte 38.502
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.502


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021264 0 0 0 0 0 83 34 35 44 34 11 23
2021/2022662 1 69 12 30 18 10 27 23 10 97 120 245
2022/20231.733 164 180 78 136 115 158 36 91 691 14 43 27
2023/2024456 32 76 22 42 39 103 6 46 2 29 4 55
2024/20252.637 55 36 71 169 171 79 86 491 610 205 269 395
2025/20262.796 440 465 586 506 753 46 0 0 0 0 0 0
Totale 9.790